Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD

Authors:

Abstract
No abstract available
Funding Information
  • Rehabilitation Research and Development Service
  • University Hospitals of Cleveland
  • U.S. Department of Veterans Affairs

This publication has 11 references indexed in Scilit: